To provide a review of currently licensed enteric vaccines and their efficacy based on completed field trials.
INTRODUCTION
Public health efforts over the last few decades have resulted in significantly fewer deaths due to diarrheal diseases worldwide. Yet, enteric infections continue to claim 1.9 million lives of children under 5 years of age, primarily in developing countries [1] . Improvements in sanitation, healthcare, and the encouragement of exclusive breast-feeding have reduced mortality considerably in developing countries [2] . However, while mortality has declined, surviving children suffer from repeated diarrheal episodes that affect growth, nutrition, and cognitive abilities [3] . In industrialized countries, diarrheal diseases rarely cause death, but remain a major cause of outpatient and emergency room visits. Additionally, health-related and financial burdens of food-borne outbreaks worldwide have been substantial [4] [5] [6] . Furthermore, civilian and military travelers from industrialized countries to endemic areas are at great risk for developing travelers' diarrhea, which occurs despite dietary caution, strict hygiene, prophylactic antimicrobials, and travel vaccines [7] .
Although children are at greatest risk for adverse outcomes due to enteric infections, other groups of immune-compromised individuals are a major concern. Long-term survivors with HIV-infection, organ transplant recipients on immune-suppression, cancer patients on chemotherapy, senior citizens with multiple comorbidities, and pregnant women are also extremely vulnerable to enteric infections. Despite the availability of appropriate medical care, preventive vaccines remain the best and most costeffective way to control enteric infections. In this article, we elected to only review enteric vaccines that are currently licensed for use, recognizing that vaccines do not exist for most enteric pathogens. Furthermore, we focused only on reviewing existing data from human efficacy trials and other selected enteric vaccine candidates with promising efficacy from early clinical testing. Finally, we discuss the shortcomings of these vaccines and make an argument for continued efforts to develop nextgeneration vaccines.
CHOLERA VACCINES
Acute intestinal infections with the bacterium Vibrio cholerae occur through ingestion of fecally contaminated food and water. Poverty, lack of hygiene, and poor sanitation are major determinants of the severity of outbreaks.
Currently, there are three licensed orally administered cholera vaccines available. Dukoral is a monovalent vaccine composed of killed whole V. cholerae O1 cells and recombinant cholera B subunits, produced by Crucell. This vaccine is administered as two oral doses 1-6 weeks apart when given to children at least 6 years of age and adults, and as three oral doses 1-6 weeks apart for children 2 to 5 years of age. Large field trials in Bangladesh in the 1980s demonstrated 85% protective efficacy within 6 months of vaccination; thereafter, there was 62, 58, and 18% efficacy after 1, 2, and 3 years, respectively [8] . Less successful field trials were performed in the 1990s in Peru that showed no protection during the first year after receiving two doses of vaccine [9] , but after a single booster dose 10 months after the primary series, the vaccine conferred 61% protection [10] . Furthermore, in another Peruvian trial among military recruits, there was 86% protection during the first 6 months after vaccination [11] . In 2003-2004 in Beira, Mozambique, vaccine effectiveness was 84% within the first 6 months of vaccination [12] . Dukoral is available in 70 countries, but not in the United States. Despite the proven efficacy of Dukoral, the two-dose requirement and the cost of vaccine (retail price USD$50-75/dose [13] ) detract from its usefulness in reactive mass vaccination campaigns. Therefore, its use is essentially limited to affluent travelers of developed countries.
Two additional and nearly identical oral cholera vaccines are available. A bivalent vaccine composed of killed whole cells of V. cholerae O1 and O139 is available only in Vietnam, known as mORC-Vax. After successful technology transfer, a similar bivalent vaccine, known as Shanchol, was introduced to Indian and international markets. These two cholera vaccines are given as two oral doses 14 days apart in individuals at least 1 year of age. The bivalent vaccine demonstrated 50% protection in the 3-5 years following vaccination, in Hue, Vietnam [14] . As a result, Vietnam is the only country to have introduced oral cholera vaccination in their immunization schedule. The Shanchol version of the bivalent vaccine is currently undergoing a 5-year field trial in Kolkata, India, and the 2-year postvaccination interim analysis has shown 67% protective efficacy [15] . Another large efficacy field trial, with Shanchol, is currently ongoing in Dhaka, Bangladesh [16] . Although the cost of these bivalent vaccines is affordable (USD$1-2/dose [13] ), the two-dose requirement continues to limit its use in reactive mass vaccination campaigns. As a result, a pilot program using Shanchol in Orissa, India, is currently studying the feasibility, acceptability, and cost of implementing mass vaccination [17] .
A single-dose live-attenuated oral cholera vaccine, capable of eliciting vibriocidal antibodies and protection within 8 days from administration [18, 19] , was available until 2004 when the manufacturer voluntarily suspended production due to the perception of limited market potential. The vaccine, called CVD 103-HgR, is a V. cholerae O1 strain expressing an inactivated B subunit. Among healthy U.S. adults, vaccination demonstrated more than 90% protective efficacy [19] [20] [21] . However, when a large field trial was performed in North Jakarta, Indonesia, there was a concomitant drop in cholera incidence during the observation period of the study, such that the trial was unable to demonstrate significant protection during the 4-year follow-up [22] . Furthermore, the high prevalence of environmental enteropathy and small bowel bacterial overgrowth in persons of developing countries can result in a true reduction in immunogenicity (and therefore efficacy), when compared with responses of those from industrialized countries, with relatively sterile environments [23 & ]. However, a reactive mass vaccination campaign using CVD 103-HgR during an outbreak in Micronesia was associated with 79% vaccine efficacy [18] . Manufacture and recommercialization of this product is currently under consideration by a U.S.-based company. Nonetheless, the most optimal next-generation cholera vaccines should aspire to be
KEY POINTS
Only a few licensed vaccines are currently available.
Existing vaccines are not optimal.
Vaccines have lower efficacy in high disease prevalence countries.
Effective vaccines are still unaffordable in endemic countries that need them most. single dose, of long duration, and of high efficacy among residents of endemic areas.
ROTAVIRUS VACCINES
Rotavirus infections are the leading cause of severe childhood diarrhea and are annually responsible for over half a million deaths and 2.4 million hospitalizations globally [24, 25] . Therefore, when the first rotavirus vaccine, Rotashield, was removed from the market a year after licensure, for rare cases of intussusception, there was a concern for the loss of a vaccine with considerable potential public health benefit in developing countries. It was another 7 years before subsequent rotavirus vaccines were licensed.
Two oral live-attenuated rotavirus vaccines are now licensed and available internationally. In 2006, the WHO recommended that these vaccines be incorporated into the routine immunization of infants of industrialized countries [26] . However, it was not until 2009, after review of newer clinical efficacy data in developing countries, that the WHO recommended that these two rotavirus vaccines be included into national immunization programs worldwide [27] .
The monovalent, live-attenuated, oral human rotavirus vaccine, Rotarix, is given as a two-dose regimen at 2 and 4 months of age. Vaccine efficacy at preventing severe rotavirus-associated gastroenteritis was 80-96% when used in industrialized countries [28] [29] [30] [31] . Therefore, the efficacy of either rotavirus vaccine is a function of the country-specific rotavirus mortality rate among children less than 5 years of age. The estimate for efficacy is 50-64% in countries with the highest mortality rates, 72-85% in countries with intermediate mortality rates, and more than 85% in countries with low mortality rates. But despite the lower vaccine efficacy in developing countries, the higher burden of severity associated with rotavirus still translates to greater absolute reductions in morbidity and mortality with vaccination. Nonetheless, the cost of rotavirus vaccines is currently prohibitive for low-income countries.
TYPHOID VACCINES
Salmonella infections in humans are almost exclusively restricted to a single species, Salmonella enterica, which may cause a range of diseases, including invasive infections (e.g., enteric fever), gastroenteritis, and diarrhea. Enteric fever is principally caused by S. enterica subspecies enterica serovar Typhi (Salmonella Typhi), but can also be caused by serovars Paratyphi A, B, or C (Salmonella Paratyphi). Typhoid fever is estimated to be responsible for more than 21 million illnesses and more than 200 000 deaths globally per year, whereas paratyphoid fever is responsible for more than 5 million illnesses [37]. The only two currently available vaccines for Salmonella infections are against S. Typhi.
An oral, live-attenuated Ty2 strain of S. Typhi, designated Ty21a, is available as a lyophilized vaccine in an enteric-coated capsule or in a liquid formulation. The efficacy of Ty21a was demonstrated by field trials in endemic countries in the 1980s and 1990s but no prospective, randomized trials have been performed among travelers from nonendemic countries, leading to a wide variation in national policies for typhoid vaccine recommendations. For most of the world, Ty21a is administered as a three-dose regimen, taken on alternate days. However, in the United States and Canada, a four-dose regimen (with the enteric-coated capsule formulation) has been adopted, due to higher efficacy observed during field studies in Chilean children [38] . The vaccine is approved for use in children at least 5 years of age, except in the United States and United Kingdom where it is recommended for children at least 6 years of age. Booster doses are recommended annually in endemic countries and the United Kingdom, but every 5 years in the United States and every 7 years in Canada. Field trials in Egypt, Chile, and Indonesia demonstrated 96, 67, and 42-53% protection, respectively, during approximately 3 years of observation [39] [40] [41] . The liquid formulation of the vaccine (not available in the United States) provides more protection than the enteric-coated capsule formulation [41, 42] and the duration of protection may be up to 5-7 years [43] . The requirement for cold temperature storage, multiple doses, and the lack of optimal protection has diminished enthusiasm for this vaccine as a public health tool in endemic countries. Therefore, its use is primarily limited to travelers from developed countries. One potential advantage of Ty21a may be partial protection against S. Paratyphi [44, 45] , but prospective trials have not been performed to formally evaluate this indirect efficacy.
Another group of vaccines are the single-injection, purified Vi capsular polysaccharide (Vi PS) vaccines, which are commercially available from two international manufacturers and several lowcost producers in developing countries. Children at least 2 years of age may be vaccinated and a booster dose is recommended after 3 years. The efficacy of Vi PS is 68% for the first year after immunization, with waning protection over 3 years [46] [47] [48] [49] . Until recently, there has been reluctance to incorporate Vi PS vaccines into the immunization programs of endemic countries, yet recent data from Kolkata, India, suggests that significant herd protection can be generated with only 60% coverage rates [50] .
Due to the short duration of protection and the inability to immunize children less than 2 years of age with the T-cell independent Vi PS vaccine, conjugate vaccines are in development. A Vi polysaccharide conjugated to a detoxified recombinant exotoxin A from Pseudomonas aeruginosa (Vi-rEPA) vaccine demonstrated more than 90% protection [51] for a duration of almost 4 years [52] . Vaccines effective at protecting against other agents of enteric fever, such as S. Paratyphi and nontyphoidal Salmonella, are warranted.
ENTEROTOXIGENIC ESCHERICHIA COLI VACCINES
Enterotoxigenic Escherichia coli (ETEC), the most common pathogen causing travelers' diarrhea [53] , expresses plasmid-encoded secretory toxins, including the cholera-like heat-labile enterotoxin (labile toxin or LT). However, for up to 40% of travelers' diarrhea a causal pathogen is not identified.
The oral cholera vaccine, Dukoral, which contains the cholera B subunit, is capable of conferring short-lasting protection against ETEC, by eliciting antibodies cross-reactive to labile toxin. The first indication of cross-protection against ETEC was shown during field trials in the 1980s in Matlab, Bangladesh, where 86% protective efficacy was demonstrated 3 months following vaccination [54] . Due to the lack of longer lasting protection (beyond 3 months), the vaccine's effectiveness is limited to that of travelers to endemic countries. Among Finnish travelers to Morocco, there was 52% protection against ETEC diarrhea, and 71% protection against mixed infections (ETEC plus another pathogen) [55] . Among U.S. students attending summer programs in Mexico, there was 50% protection against ETEC [56] .
Building upon these data, an ETEC-specific vaccine was developed; based on killed whole-cell ETEC, chosen to express the most prevalent colonization factor antigens, plus recombinant cholera B subunits. In U.S. travelers to Guatemala and Mexico, two oral doses of this vaccine, separated by 7-21 days conferred 77% protection against more severe ETEC symptoms, but presented no reduction in the overall rate of ETEC diarrhea [57] .
Another novel ETEC-specific vaccine involves the transcutaneous delivery of labile toxin, by a patch. U.S. volunteers immunized by wearing the patch on days 0, 21, and 42, were protected from severe diarrheal symptoms, but not from diarrhea, when challenged with virulent ETEC [58] . In a subsequent field trial, U.S. travelers to Guatemala or Mexico, immunized with two applications of labile toxin-containing patch separated by 2-3 weeks, experienced 75% protection from moderate to severe ETEC diarrhea [59] . This labile toxin patch vaccine is currently being evaluated in another phase II trial of travelers to Asia [60] and in a phase III pivotal efficacy trial in Central America [61] .
Although travelers' diarrhea afflicts 15-50% of persons traveling to developing countries and is estimated to result in 40 million cases annually [62] , ETEC only consists of about one-third of all cases. Improved travelers' diarrhea vaccines will need to also be directed against the other common diarrheagenic pathogens (e.g., other E. coli, Campylobacter, Shigella, Salmonella, noncholera Vibrios, Giardia, Cryptosporidium, and noroviruses).
NOROVIRUS VACCINE
Noroviruses are responsible for more than 90% of nonbacterial gastroenteritis globally [63, 64] . They are highly infectious viruses that have the ability to spread rapidly in closed settings, such as hospitals, nursing homes, cruise ships, military barracks, and university campuses [65] [66] [67] [68] . About 23 million cases annually occur in the United States and up to 200 000 deaths of children less than 5 years occur every year in developing countries [69] . Vaccine development has been hampered due to the inability to culture the virus in cell culture and because of the absence of a good animal model of infection. However, recently developed noninfectious norovirus virus-like particles (VLPs) have proven to be highly immunogenic [70, 71] , and a recent phase I study of a monovalent adjuvanted Norwalk VLP vaccine was found to be well tolerated and strongly immunogenic, when administered nasally [72] . Moreover, two nasal doses of the vaccine, given 21 days apart, provided 47% protection against acute gastroenteritis in a subsequent Phase II experimental challenge trial [73] . These data provide the proof-of-concept that a nasally delivered vaccine may protect against an enteric pathogen.
Vaccines for enteric infections Chen and El-Kamary CONCLUSION Improvements in healthcare, sanitation and public health have led to significant reductions in morbidity and mortality from enteric infections. Like other infectious diseases, vaccines remain the best public health tool, but as outlined in this article, only a few enteric vaccines exist. For those available vaccines, greater accessibility, utilization, and distribution are needed, especially for impoverished countries where the disease burden is greatest. As new vaccines are developed, earlier dissemination and adoption of affordable vaccines by developing countries is essential to reduce the high burden of disease, and to prevent dissemination to industrialized countries via travelers and contaminated food products. 
